Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis

Frontiers in Cellular and Infection Microbiology

Sarah E. Murphy¹  Tihana Bicanic² 

[1] Institute of Infection & Immunity, St George’s University of London, London, United Kingdom;Institute of Infection & Immunity, St George’s University of London, London, United Kingdom;Clinical Academic Group in Infection and Immunity, St. George’s University Hospital National Health Service (NHS) Foundation Trust, London, United Kingdom;

关键词: Candida;    invasive candidiasis;    candidaemia;    antifungal resistance;    antifungal drugs;    drug therapy;    drug resistance;    antimicrobial resistance;   

DOI  :  10.3389/fcimb.2021.759408

来源: Frontiers

【 摘 要 】

Candida species are the leading cause of invasive fungal infections worldwide and are associated with acute mortality rates of ~50%. Mortality rates are further augmented in the context of host immunosuppression and infection with drug-resistant Candida species. In this review, we outline antifungal drugs already in clinical use for invasive candidiasis and candidaemia, their targets and mechanisms of resistance in clinically relevant Candida species, encompassing not only classical resistance, but also heteroresistance and tolerance. We describe novel antifungal agents and targets in pre-clinical and clinical development, including their spectrum of activity, antifungal target, clinical trial data and potential in treatment of drug-resistant Candida. Lastly, we discuss the use of combination therapy between conventional and repurposed agents as a potential strategy to combat the threat of emerging resistance in Candida.

【 授权许可】

CC BY